Exploring how the genome can improve cancer immunotherapy
Harnessing the repetitive genome for cancer immunotherapy
['FUNDING_CAREER'] · DANA-FARBER CANCER INST · NIH-10894129
This study is exploring how certain parts of our DNA can help improve cancer treatments by boosting the immune system's ability to fight tumors, and it's designed to benefit patients looking for better options in their cancer care.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10894129 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the repetitive genome in cancer and how it can be harnessed to enhance immunotherapy treatments. Led by Dr. Gabriel Griffin, the project aims to investigate the basic mechanisms of immune regulation in cancer, particularly through the study of transposable elements and genome topology. Patients may benefit from advancements in cancer treatment as the research seeks to uncover new strategies for improving immune responses against tumors. The project is part of a five-year training program that combines laboratory work with mentorship from leading experts in cancer biology.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who may benefit from innovative immunotherapy approaches.
Not a fit: Patients with non-cancerous conditions or those not eligible for immunotherapy may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that better harness the body's immune system to fight cancer.
How similar studies have performed: Other research in cancer epigenetics and immunotherapy has shown promising results, indicating that this approach has the potential for significant breakthroughs.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRIFFIN, GABRIEL K. — DANA-FARBER CANCER INST
- Study coordinator: GRIFFIN, GABRIEL K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Burn injury